The isolates in a collection of 170 Aspergillus fumigatus isolates recovered from 114 patients and 21 different medical centers in The Netherlands over a period of 53 years were tested for the presence of resistance to itraconazole and voriconazole according to the guidelines of NCCLS document M38-P and by the E-test. Three isolates were highly resistant to itraconazole, and voriconazole MICs were low for all isolates.Over the past few decades the incidence of invasive fungal infections has increased, especially those caused by Aspergillus species (11, 16). The treatment of choice for infected patients remains amphotericin B, although alternative drugs with activities against Aspergillus species are becoming available for clinical use, including the antifungal azoles itraconazole and voriconazole. Itraconazole is highly active against Aspergillus species but has been used almost exclusively as follow-up therapy in patients with invasive aspergillosis. However, with the availability of a new intravenous formulation of itraconazole and an oral solution, first-line therapy may become an option (1). Voriconazole is active against a wide range of filamentous molds including Aspergillus species. The drug can be administered both intravenously and orally and was found to be superior to amphotericin B as first-line therapy for the treatment of invasive aspergillosis ( Although testing of the susceptibilities of Aspergillus fumigatus isolates to amphotericin B in vitro is problematic, resistance to azoles can be detected (3,5,6). The in vitro resistance of A. fumigatus to itraconazole was confirmed by use of animal experimental models (3, 5). However, the prevalence of resistance to itraconazole and voriconazole among A. fumigatus isolates is unknown. In the present study we investigated the prevalence of resistance among A. fumigatus isolates that had been cultured from patients admitted to hospitals throughout The Netherlands.(This work was presented in part at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., 24 to 27 September 1998.) Medical microbiology laboratories in The Netherlands were asked to send A. fumigatus isolates that had been cultured from clinical samples at their hospitals. In addition, the database of the collection of the Centraalbureau voor Schimmelcultures (CBS) was searched for A. fumigatus isolates that had been cultured from clinical specimens from Dutch patients. The isolates were subcultured onto Sabouraud glucose agar plates supplemented with 0.5% chloramphenicol; the plates were incubated at 29°C for 7 days, and the identifications were confirmed. Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258 were used as quality controls. In addition, an itraconazole-susceptible A. fumigatus isolate (isolate AF71; MIC, 0.25 g/ml) and an itraconazole-resistant A. fumigatus isolate (isolate AF91; MIC, Ͼ64 g/ml) were included in each test (5).Reference-grade lots of itraconazole (Janssen-Cilag, Tilburg, The Netherlands) and voriconazole (Pfizer Centra...